Raltegravir is unusually widely usable. The reasons for choosing something else are generally practical rather than clinical.
Who should avoid it on clinical grounds?
Anyone with a documented hypersensitivity to it. Anyone with significant integrase resistance, depending on the pattern, where its lower barrier means it may no longer be active.
What about existing integrase resistance?
The key clinical limitation. Raltegravir resistance can emerge through a single mutation in some pathways, and virus resistant to it may still respond to dolutegravir at twice-daily dosing. The reverse is rarely true.
What about the resistance barrier generally?
Lower than dolutegravir or bictegravir. Where adherence is likely to be irregular, a higher-barrier regimen is safer. That is a matching exercise rather than a judgement about anyone.
What about twice-daily dosing?
The commonest practical reason people choose something else. Two doses a day is harder to sustain than one, particularly with irregular work or travel. The once-daily formulation addresses this if you ask.
What about the absence of a single tablet?
A real disadvantage. Raltegravir always means taking at least two products, where dolutegravir and bictegravir come in complete single-tablet regimens. If pill burden matters to you, that is a legitimate reason.
What about muscle problems?
A previous episode of rhabdomyolysis or significant myopathy is worth raising. It is uncommon with raltegravir and a history is a reason for caution and closer attention rather than automatic exclusion.
What about liver impairment?
Not adequately studied in severe hepatic impairment. Mild to moderate impairment requires no adjustment.
What about kidney impairment?
Not a constraint on raltegravir at any level, which is one of its advantages. The limitation comes from whatever backbone accompanies it.
What about pregnancy?
An argument in its favour rather than against. It has one of the better established records in pregnancy, reduces viral load rapidly, and its minimal interaction profile is helpful where other medicines are involved.
What about tuberculosis treatment?
Also an argument in its favour. It is one of few antiretrovirals usable with rifampicin, by doubling the dose. Where tuberculosis treatment is needed, raltegravir may be the reason a workable regimen exists.
When is it a particularly good choice?
Where someone takes several medicines for other conditions, where a boosted regimen has caused interaction problems, in pregnancy, alongside tuberculosis treatment, and for anyone who has not tolerated other options.
What are the alternatives?
Dolutegravir, once daily with a higher resistance barrier and available in several combinations. Bictegravir, in a single tablet. Cabotegravir for injections. Doravirine or boosted darunavir where the class is unsuitable.
Is it being phased out?
Used less than it was, and not disappearing. Its interaction profile keeps it relevant in situations where newer drugs are harder to fit.
Can you switch away easily?
Yes. Switching between integrase-based regimens is routine and suppression is maintained provided the new one is fully active.
Who decides?
You do, with a clinician. Dosing frequency and pill burden are legitimate reasons to prefer something else, and they do not need justifying on clinical grounds.